It was a pleasure to speak with Prof. Rohit Loomba (University of California, San Diego, CA, USA) about the rationale for the use of the novel SPPARM inhibitor, pemafibrate, in the treatment of NAFLD.
Part 2 of our discussion can be found here.
His presentation entitled ‘Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARM alpha), improves liver stiffness by MRE and serum liver and lipid parameters in NAFLD; a randomized, double-blind, placebo-controlled phase 2 trial’ was given at EASL ILC 2021, 23-26 June.
Disclosures: Prof. Rohit Loomba serves as a consultant for Anylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myer Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse Bio, Inipharm, Intercept, Ionis, Janssen Inc., Madrigal, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Pfizer, Sagimet, 89bio, and Viking Therapeutics. In addition, his institution has received grant support from Allergan, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Genfit, Gilead, Intercept, Inventiva, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Pfizer and Siemens. He is also a co-founder of Liponexus, Inc.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the EASL ILC 2021, 23-26 June.
